Background Renin-angiotensin-system inhibitors (RASi), that include angiotensin converting
enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) reduce proteinuria …

AIMS. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers
(ARBs) prevent the progression of diabetic nephropathy (DN). Studies suggest that …

Hypertension is a comorbidity of Type 2 diabetes, and blood pressure lowering has been
shown to reduce cardiovascular (CV) and renal disease progression in this population …

Background There is much uncertainty regarding the relative effects of angiotensin-
converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) in …

Objective To assess the effects of different classes of antihypertensive treatments, including
monotherapy and combination therapy, on survival and major renal outcomes in patients …

Background: In some patients with renal disease, use of angiotensin-converting enzyme
(ACE) inhibitors is thought to improve renal function, whereas in others their use leads to …

Background A consensus has emerged that angiotensin-converting-enzyme (ACE)
inhibitors and angiotensin-II receptor blockers (ARBs) have specific renoprotective effects …

Abstract Background/Aims: Whether angiotensin converting enzyme inhibitors (ACE) and
angiotensin receptor blockers (ARB) are differentially associated with reductions in …

The aim of this study was to estimate the cost‐effectiveness of renin‐angiotensin‐
aldosterone system blockers in patients with diabetic nephropathy. A cost‐effectiveness …

Objective: Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme
(ACE) inhibitors are known to reduce proteinuria and have been the first-line agents in the …